Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGN NYSE:BVS NYSE:ELMD NASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$16.73+2.2%$14.22$9.22▼$21.00$769.75M1.02832,663 shs914,211 shsBVSBioventus$6.84-4.6%$6.97$5.81▼$14.38$565.52M0.84396,458 shs462,397 shsELMDElectromed$24.39-1.3%$20.62$17.73▼$35.56$203.63M0.5485,159 shs70,357 shsSIBNSiBone$15.10-0.3%$16.57$11.70▼$20.05$651.43M0.81421,773 shs299,760 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen-0.24%+2.06%+9.65%+71.77%+18.71%BVSBioventus-0.83%-0.55%-2.71%+12.91%-35.81%ELMDElectromed+3.43%-1.04%+30.48%+23.07%+35.49%SIBNSiBone-3.57%-6.14%-2.07%-11.72%-3.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$16.73+2.2%$14.22$9.22▼$21.00$769.75M1.02832,663 shs914,211 shsBVSBioventus$6.84-4.6%$6.97$5.81▼$14.38$565.52M0.84396,458 shs462,397 shsELMDElectromed$24.39-1.3%$20.62$17.73▼$35.56$203.63M0.5485,159 shs70,357 shsSIBNSiBone$15.10-0.3%$16.57$11.70▼$20.05$651.43M0.81421,773 shs299,760 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen-0.24%+2.06%+9.65%+71.77%+18.71%BVSBioventus-0.83%-0.55%-2.71%+12.91%-35.81%ELMDElectromed+3.43%-1.04%+30.48%+23.07%+35.49%SIBNSiBone-3.57%-6.14%-2.07%-11.72%-3.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$26.0055.41% UpsideBVSBioventus 2.75Moderate Buy$13.75101.02% UpsideELMDElectromed 3.33Buy$36.2548.63% UpsideSIBNSiBone 3.00Buy$23.6756.73% UpsideCurrent Analyst Ratings BreakdownLatest ELMD, AXGN, SIBN, and BVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025ELMDElectromedLoop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$36.008/27/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $35.008/27/2025ELMDElectromedLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.008/11/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$25.008/5/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$25.007/22/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$29.007/21/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$12.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$187.34M4.11N/AN/A$2.36 per share7.09BVSBioventus$564.14M1.00$0.54 per share12.58$2.80 per share2.44ELMDElectromed$64M3.18$0.59 per share41.36$5.10 per share4.78SIBNSiBone$185.26M3.52N/AN/A$3.98 per share3.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$9.96M-$0.10N/AN/AN/A-2.29%-4.43%-2.34%11/6/2025 (Estimated)BVSBioventus-$156.23MN/AN/A14.87N/A-7.11%15.61%4.01%N/AELMDElectromed$5.15M$0.8432.52∞N/A11.34%15.71%13.37%N/ASIBNSiBone-$30.91M-$0.56N/AN/AN/A-12.83%-14.20%-10.38%11/11/2025 (Estimated)Latest ELMD, AXGN, SIBN, and BVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025SIBNSiBone-$0.19-$0.14+$0.05-$0.14$48.12 million$48.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ABVSBioventusN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.594.142.67BVSBioventus1.851.410.99ELMDElectromedN/A5.104.74SIBNSiBone0.218.387.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%BVSBioventus62.94%ELMDElectromed40.82%SIBNSiBone98.11%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%BVSBioventus33.00%ELMDElectromed14.00%SIBNSiBone4.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45046.01 million44.73 millionOptionableBVSBioventus1,20082.68 million54.46 millionNot OptionableELMDElectromed1608.35 million7.36 millionOptionableSIBNSiBone35043.14 million41.46 millionOptionableELMD, AXGN, SIBN, and BVS HeadlinesRecent News About These CompaniesSI-BONE, Inc. (SIBN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comTrexquant Investment LP Has $1.62 Million Holdings in SiBone $SIBNSeptember 8, 2025 | marketbeat.comGranahan Investment Management LLC Decreases Holdings in SiBone $SIBNSeptember 7, 2025 | marketbeat.comFirst Light Asset Management LLC Acquires 475,426 Shares of SiBone $SIBNSeptember 4, 2025 | marketbeat.comParadigm Capital Management Inc. NY Trims Stock Holdings in SiBone $SIBNSeptember 2, 2025 | marketbeat.comWalleye Capital LLC Buys Shares of 80,910 SiBone $SIBNSeptember 2, 2025 | marketbeat.comChamplain Investment Partners LLC Decreases Stake in SiBone $SIBNAugust 30, 2025 | marketbeat.comVanguard Group Inc. Increases Holdings in SiBone $SIBNAugust 29, 2025 | marketbeat.comAlphaQuest LLC Purchases 25,764 Shares of SiBone $SIBNAugust 28, 2025 | marketbeat.comRussell Investments Group Ltd. Has $2.83 Million Stake in SiBone $SIBNAugust 27, 2025 | marketbeat.comSI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025August 26, 2025 | globenewswire.comAmerican Century Companies Inc. Purchases 264,254 Shares of SiBone $SIBNAugust 23, 2025 | marketbeat.com1,326,100 Shares in SiBone $SIBN Acquired by Nuveen LLCAugust 22, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) SVP Sells $52,065.56 in StockAugust 21, 2025 | insidertrades.comTocqueville Asset Management L.P. Has $3.58 Million Stake in SiBone (NASDAQ:SIBN)August 19, 2025 | marketbeat.comInsider Selling: SiBone (NASDAQ:SIBN) Director Sells 12,132 Shares of StockAugust 12, 2025 | insidertrades.comSI-Bone Reports Strong Q2 2025 Financial ResultsAugust 5, 2025 | msn.comSI-BONE, Inc. (SIBN) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comSI-BONE, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 4, 2025 | seekingalpha.comSi-Bone (SIBN) Reports Q2 Loss, Beats Revenue EstimatesAugust 4, 2025 | zacks.comSI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 GuidanceAugust 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELMD, AXGN, SIBN, and BVS Company DescriptionsAxoGen NASDAQ:AXGN$16.73 +0.36 (+2.20%) Closing price 04:00 PM EasternExtended Trading$16.51 -0.22 (-1.31%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Bioventus NYSE:BVS$6.84 -0.33 (-4.60%) Closing price 04:00 PM EasternExtended Trading$6.84 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Electromed NYSE:ELMD$24.39 -0.31 (-1.26%) Closing price 04:00 PM EasternExtended Trading$24.38 -0.02 (-0.06%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.SiBone NASDAQ:SIBN$15.10 -0.04 (-0.26%) Closing price 04:00 PM EasternExtended Trading$15.08 -0.01 (-0.10%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
